U.S. markets closed

PharmaCielo Ltd. (PCLO.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.5800-0.0300 (-4.92%)
At close: 3:55PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6100
Open0.6200
Bid0.5800 x 0
Ask0.6200 x 0
Day's Range0.5800 - 0.6300
52 Week Range0.5000 - 5.9500
Volume251,191
Avg. Volume163,422
Market Cap68.594M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3410
Earnings DateSep 01, 2020 - Sep 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export
      CNW Group

      PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export

      TORONTO and RIONEGRO, Colombia , July 8, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (PCLO.V) (PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that the Colombian government granted the Company authorization for the 2020 commercial cultivation, production and export of high-THC medicinal cannabis extracts, in fulfilment of existing sales agreements. The commercial quotas obtained from the ministries of Justice and Health, enable the Company to immediately begin cultivation and processing of 10 tonnes of THC-dominant dry flower.

    • PharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering
      CNW Group

      PharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering

      TORONTO , July 3, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (PCLOF) is pleased to announce that it has closed its previously announced "bought deal" offering (the "Offering") of common shares conducted by a syndicate of underwriters, co-led by Cormark Securities Inc. and Stifel GMP (collectively, the "Underwriters"). The Company issued 6,388,940 common shares at a price of $0.72 per common share (the "Offering Price") for aggregate gross proceeds of $4,600,036.80 , including proceeds from the exercise in full of the Underwriters' over-allotment option to purchase 833,340 additional common shares.

    • PharmaCielo Ltd. Files Final Prospectus for $4 Million Bought Deal Offering
      CNW Group

      PharmaCielo Ltd. Files Final Prospectus for $4 Million Bought Deal Offering

      TORONTO , June 29, 2020 /CNW/ - PharmaCielo Ltd. (the "Company" or "PharmaCielo") (PCLO.V) (PCLOF) is pleased to announce that it has filed a (final) short form prospectus with the securities regulatory authorities in British Columbia , Alberta , Ontario and Quebec in connection with its previously announced $4 million "bought deal" offering of common shares (the "Offering"), co-led by Cormark Securities Inc. and Stifel GMP. The Offering is expected to close on or about July 3, 2020 and is subject to regulatory approval including that of the TSX Venture Exchange. The net proceeds of the Offering will be used for non-operational payroll expenses of PharmaCielo Colombia S.A.S. ("PharmaCielo Colombia"), non-operational payroll taxes of PharmaCielo Colombia, purchase of ethanol to be used for extraction purposes and other working capital and general corporate purposes.